Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.65 |
| ▸ | GABRP | O00591 | 1/20 | 0.64 |
| ▸ | GABRD | O14764 | 1/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.64 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.64 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.64 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.64 |
| ▸ | GABRE | P78334 | 1/20 | 0.64 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.64 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5894417 | 0.85 | RAB9A (0.69) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL4954977 | 0.84 | GPR84 (0.77) | RAB9ANPC1MEN1KMT2AGABRP | |
| SCHEMBL5768987 | 0.83 | PBRM1 (0.66) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30712070 | 0.83 | GABRP (0.72) | RAB9ANPC1MEN1KMT2AGABRP | |
| SCHEMBL30712073 | 0.83 | ALOX5 (0.63) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL19459867 | 0.83 | ALOX5 (0.63) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL12215128 | 0.81 | PBRM1 (0.73) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL32319858 | 0.81 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL11903794 | 0.81 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2ACASP3 | |
| SCHEMBL21366456 | 0.80 | IGF1R (0.67) | RAB9ANPC1MEN1KMT2AGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | QUEST VENTURES LTD. (GB) | 2013-06-13 | — | — | US | claimed |
| US-20240383850-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-11-21 | — | — | US | disclosed |
| WO-2023019367-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023019367-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| US-9951058-B2 | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) | 2018-04-24 | — | — | US | disclosed |
| US-9790197-B2 | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) | 2017-10-17 | — | — | US | disclosed |
| EP-2083014-A2 | Inhibitors of interleukin-1ß converting enzyme | Vertex Pharmceuticals Incorporated (US) | 2009-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383850-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR5A, TPH2 | RAB9A 1571/4885NPC1 2976/4885MEN1 1887/4885 |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | FAAH, FAAH2, MGLL | RAB9A 914/4885NPC1 3553/4885MEN1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.